Immune Design
Feb 24, 2015

Immune Design to Present at Upcoming Investment Conferences

SEATTLE and SOUTH SAN FRANCISCO, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at two investor conferences in March.

Cowen and Company 35th Annual Health Care Conference
Tuesday, March 3, 2015 at 8:00 a.m. Eastern Time in Boston.

Barclays Global Healthcare Conference
Thursday, March 12, 2015 at 1:35 p.m. Eastern Time, in Miami.

A live webcast of each presentation will be available online from the investor relations page of the company's corporate website at http://ir.immunedesign.com/events.cfm. After the live webcast, an archive of each presentation will be available on the company website.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors, to fight cancer and other chronic diseases. Immune Design's three on-going immuno-oncology clinical programs are the product of its two synergistic discovery platforms, ZVexTM and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.

CONTACT: Media Contact

         Julie Rathbun

         Rathbun Communications

         julie@rathbuncomm.com

         206-769-9219

         

         Investor Contact

         Robert H. Uhl

         Westwicke Partners

         robert.uhl@westwicke.com

         858-356-5932